DalsnaFinance

Adaptive Biotechnologies Corp $ADPT

Health Care

Russell 2000 Washington
Create a scorecard
$24.41
-0.92 (-3.63%)
As of Oct 22, 2026, 9:31 PM EDT · cached
Price history
Loading chart…

Adaptive Biotechnologies Corp (ADPT) is trading down at $24.41 (-3.63%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: June 27, 2019 · $20.00 offering · NASDAQ · View IPO details →

Adaptive Biotechnologies Corp revenue & net income history (FY2017–FY2025)

RevenueNet incomeNet margin (right axis, %)
$277.0M$25.9M−$225.3MFY2017 revenue: $38.4MFY2017 net income: −$42.8M · Net margin −111.4%'17FY2018 revenue: $55.7MFY2018 net income: −$46.4M · Net margin −83.4%'18FY2019 revenue: $85.1MFY2019 net income: −$68.6M · Net margin −80.6%'19FY2020 revenue: $98.4MFY2020 net income: −$146.2M · Net margin −148.6%'20FY2021 revenue: $154.3MFY2021 net income: −$207.3M · Net margin −134.3%'21FY2022 revenue: $185.3MFY2022 net income: −$200.2M · Net margin −108.0%'22FY2023 revenue: $170.3MFY2023 net income: −$225.3M · Net margin −132.3%'23FY2024 revenue: $179.0MFY2024 net income: −$159.5M · Net margin −89.1%'24FY2025 revenue: $277.0MFY2025 net income: −$59.5M · Net margin −21.5%'25−100%−50%0%50%FY2017 net margin: −111.4% (off the scale, which stops at −100.0%)FY2018 net margin: −83.4%FY2019 net margin: −80.6%FY2020 net margin: −148.6% (off the scale, which stops at −100.0%)FY2021 net margin: −134.3% (off the scale, which stops at −100.0%)FY2022 net margin: −108.0% (off the scale, which stops at −100.0%)FY2023 net margin: −132.3% (off the scale, which stops at −100.0%)FY2024 net margin: −89.1%FY2025 net margin: −21.5%
Adaptive Biotechnologies Corp annual financial statements
FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$38.4M$55.7M$85.1M$98.4M$154.3M$185.3M$170.3M$179.0M$277.0M
Growth (year over year)—+44.8%+52.8%+15.6%+56.9%+20.1%−8.1%+5.1%+54.8%
Gross profit$22.8M$36.0M$62.8M$75.9M$105.0M$127.4M$94.7M$106.9M$205.6M
Gross margin59.2%64.7%73.8%77.1%68.1%68.7%55.6%59.7%74.2%
Operating income−$44.5M−$49.8M−$78.4M−$152.8M−$209.0M−$200.2M−$227.0M−$162.5M−$57.1M
Operating margin−115.7%−89.4%−92.1%−155.3%−135.4%−108.0%−133.3%−90.8%−20.6%
Net income−$42.8M−$46.4M−$68.6M−$146.2M−$207.3M−$200.2M−$225.3M−$159.5M−$59.5M
Net margin−111.4%−83.4%−80.6%−148.6%−134.3%−108.0%−132.3%−89.1%−21.5%
EPS (diluted)−$3.50−$3.67−$1.01−$1.11−$1.48−$1.40−$1.56−$1.08−$0.39
Balance sheet
Cash and equivalents—$55.0M$96.6M$123.4M$139.1M$90.0M$65.1M$47.9M$70.5M
Total assets—$332.7M$912.3M$1.12B$923.3M$856.6M$661.1M$539.4M$512.7M
Total liabilities—$29.9M$341.3M$373.1M$319.2M$392.5M$352.9M$336.9M$287.7M
Long-term debt—————$125.4M$130.7M$132.4M$126.6M
Shareholders' equity−$224.6M−$258.1M$571.0M$743.3M$604.0M$464.2M$308.4M$202.7M$218.8M
Cash flow
Operating cash flow−$34.9M−$32.3M$205.4M−$149.7M−$192.7M−$183.9M−$156.3M−$95.2M−$46.0M
Capital expenditure$2.42M$6.30M$11.2M$18.8M$61.7M$16.3M$10.7M$3.66M$2.96M
Free cash flow−$37.3M−$38.6M$194.2M−$168.5M−$254.5M−$200.3M−$167.0M−$98.9M−$48.9M

From Adaptive Biotechnologies Corp's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Adaptive Biotechnologies Corp

Headquarters
Seattle, Washington From SEC filings, Oct 2026

Recent News (5)

More Health Care stocks

Browse all companies →